CABA— Cabaletta Bio, Inc.

Cabaletta Bio GAAP EPS of -$0.39 beats by $0.01

Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update

Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting

Cabaletta Bio prices $150M stock offering

Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering

Bristol-Myers Squibb: The CAR-T Giant The Market Is Undervaluing

Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel

Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel